Clinical Trial NCT04458857
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age Randomized, Double-Blind, Placebo-Controlled Study of Fremanezumab in Patients (6 to 17 Years) with Episodic Migraine A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age Efficacy, Safety, and Tolerability Study (Phase 3)
- ClinicalTrials.gov ID: NCT04458857
- Not accepting healthy volunteers
- UTSW Principal Investigator: DERYK LEE WALSH
objective
The primary objective of the study is to evaluate the efficacy of fremanezumab as compared to placebo for the preventive treatment of chronic migraine in pediatric patients 6 to 17 years of age.